Drugs / MART-1:26-35(27L)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00028431 | Aug 2001 → Jan 2003 | melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00001832 | Aug 1999 → May 2010 | melanoma, metastatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1 26-35 (27L) | “The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) which are emulsified with IFA.” NCT00028431 ↗ |
| Modality | Peptide | “MART-1:26-35(27L) peptide” NCT00001832 ↗ |
| Route | Subcutaneous | “MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh)” NCT00001832 ↗ |